TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma.
暂无分享，去创建一个
W. Hahn | G. Getz | A. Iafrate | C. Benes | A. Bardelli | D. Juric | A. Zhu | J. Lennerz | N. Bardeesy | R. Kelley | R. Yaeger | J. Harding | D. Ting | V. Deshpande | I. Leshchiner | H. Hirai | Lei Shi | F. Fece de la Cruz | G. Siravegna | K. Patra | K. Tanabe | R. Uppot | C. Ferrone | Liudmila Elagina | Srivatsan Raghavan | L. Goyal | R. Corcoran | Janet E. Murphy | Cristina R. Ferrone | Supriya K. Saha | B. Nadres | E. V. van Seventer | T. Sagara | S. Otsuki | Raymond W S Ng | Leah Y. Liu | P. Vu | Heather A. Shahzade | I. Fetter | Ron Arellano | I. Baiev | Stephanie Reyes | William C. Hahn | R. Kelley | I. Dey‐Guha | Raymond W. S. Ng | R. Ng | Brandon Nadres | E. V. Van Seventer | Ignaty Leschiner | Andrew X. Zhu | Jochen K. Lennerz | Kenneth K. Tanabe | James J. Harding | Leah Y. Liu | Isobel J. Fetter | David T. Ting | James J Harding